APA (7th ed.) Citation

Garcia-Manero, G., Bart, S., McCloskey, J. K., Fenaux, P., Selleslag, D., Reda, G., . . . Döhner, H. (2022, June). P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. HemaSphere.

Chicago Style (17th ed.) Citation

Garcia-Manero, G., et al. "P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY." HemaSphere Jun. 2022.

MLA (9th ed.) Citation

Garcia-Manero, G., et al. "P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY." HemaSphere, Jun. 2022.